OMOP Common Data Model and Atlas in prostate cancer research

Abstract

Prostate cancer is the second most common cancer globally, with Finland reporting 5 514 new cases in 2022 and a 5-year prognosis of 94%. Treatment options range from passive to active, influenced by patient preferences and other factors. New medications typically emerge from Randomized Controlled Trials (RCT), but these populations often lack diversity compared to typical clinical settings. The Observational Medical Outcomes Partnership (OMOP) aimed to standardize medical data through a Common Data Model (CDM). The Observational Health Data Sciences and Informatics (OHDSI) collaboration was established to support observational, evidence-based research. This project assessed the incidence and treatment of prostate cancer at TYKS and evaluated the usability of the OHDSI tool, Atlas, for data analysis. Using patient data in OMOP CDM format, the study began in summer 2021 with TAYS and HUS, forming a cohort diagnosed between January 1, 2010, and December 31, 2022. Outcomes included annual new diagnoses and Atlas's usability compared to source database figures. Atlas identified 7 376 new cases, while R script yielded 7 291. Patient age averaged 71, with common, most often metabolic comorbidities. Among diagnosed patients, 67% received treatment. There’s been a decline in Androgen Deprivation Therapy as monotherapy and a rise in combination therapies. Rates of radiotherapy and surgery have remained constant. While Atlas is a promising tool for Real World Data research, further investigation of discrepancies between OMOP-CDM and source data is necessary to optimize its use in future studies. Grammarly AI was utilized in condensing the abstract into its final form.